By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ASIT Biotech 

Avenue Ariane 5

Woluwe-Saint-Lambert    1200   Belgium
Phone: 322-264-03-90 Fax: 322-264-03-99


ASIT Biotech s.a. (formerly Biotech Tools) is a clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+TM technology platform.


May 1997


CEO: Thierry Legon

CFO: Everard van der Straten


Please click here for ASIT Biotech job opportunities.


Please click here for clinical trial information.

Key Statistics

Ownership: Private

Web Site: ASIT Biotech

Company News
ASIT Biotech Presents Its 2017 Half-Year Results And Provides Update On Its Clinical Programs 9/14/2017 8:42:47 AM
ASIT Biotech To Publish Its Half-Year 2017 Results On Thursday 14 September 2017 9/8/2017 10:23:26 AM
ASIT Biotech Presented The Immunogenicity Data Of The gp-ASIT+™ Phase III Clinical Study For The Treatment Of Grass Pollen Rhinitis At EAACI 2017 7/5/2017 10:51:31 AM
ASIT Biotech Discloses Comments From The Paul Ehrlich Institute And Presents Detailed Results On The Phase III Clinical Study Of Gp-ASIT + At EAACI 2017 6/19/2017 7:42:33 AM
ASIT Biotech To Disclose The Detailed Results Of Its Phase III Clinical Study With gp-ASIT+ For The Treatment Of Grass Pollen Rhinoconjunctivitis At EAACI 2017 5/31/2017 7:13:13 AM
ASIT Biotech Presents Its 2016 Annual Results And Recent Updates In Clinical Developments 4/12/2017 8:26:27 AM
ASIT Biotech Announces That It Has Achieved The Primary Endpoint Of The Phase I/IIa Clinical Trial With Its hdm-ASIT+ Product Candidate For House Dust Mite Rhinitis 4/5/2017 1:15:05 PM
ASIT Biotech Announces The Appointment Of Gerd Zettlmeissl As The Company’s New Chairman Of The Board 3/20/2017 9:12:14 AM
ASIT Biotech Will Publish The Results Of The Phase III Clinical Trial With Its Gp-ASIT+ Product Candidate For Treating Grass Pollen Rhinitis On 28 February, 2017 2/27/2017 9:00:01 AM